Biological characterization of a novel, orally active small molecule gonadotropin-releasing hormone (GnRH) antagonist using castrated and intact rats

被引:43
|
作者
Anderes, KL [1 ]
Luthin, DR [1 ]
Castillo, R [1 ]
Kraynov, EA [1 ]
Castro, M [1 ]
Hood, KN [1 ]
Gregory, ML [1 ]
Pathak, VP [1 ]
Christie, LC [1 ]
Paderes, G [1 ]
Vazir, H [1 ]
Ye, Q [1 ]
Anderson, MB [1 ]
May, JM [1 ]
机构
[1] La Jolla Agouron Pharmaceut Inc, Pfizer Global Res & Dev, Res Pharmacol, San Diego, CA 92121 USA
关键词
D O I
10.1124/jpet.102.046656
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Gonadotropin-releasing hormone ( GnRH) receptor antagonists have potential in treating numerous hormone-dependent pathologies including cancers of the prostate, breast, and ovary, endometriosis, and fertility disorders. An unmet clinical need exists for an orally available GnRH receptor antagonist. Guided by structure-activity relationships, ligand-based targeted library designs, and biomarker measurements, our discovery efforts have yielded a novel, small molecule GnRH receptor antagonist, 5-[(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthalenyl) methyl]-N-(2,4,6-trimethoxyphenyl)-2-furamide (CMPD1). CMPD1 bound with low nanomolar affinities to human, rat, and mouse GnRH receptors (6.0, 3.8, and 2.2 nM, respectively). CMPD1 was more than 100-fold selective for GnRH receptors versus various G-protein-coupled receptors and other enzymes and ion channels. In cells expressing recombinant rat GnRH receptors, CMPD1 was a competitive antagonist of GnRH-stimulated increases in extracellular acidification rates in Cytosensor microphysiometer assays. In cells expressing recombinant human GnRH receptors, CMPD1 was a potent inhibitor of GnRH-stimulated total inositol phosphate accumulation. The effects of CMPD1 on circulating levels of luteinizing hormone (LH) and testosterone were studied in castrated and intact male rats, respectively. Intravenous and oral administration of CMPD1 dose dependently suppressed GnRH-mediated elevations of LH in castrated male rats and testosterone in gonadintact male rats. Moreover, CMPD1, when given at 20 mg/kg i.v. to intact male rats, inhibited the elevations of LH and testosterone stimulated by the superagonist of GnRH, [D-Ala(6), desGly(10)] GnRH ( GnRH-A). These data suggest that CMPD1 is a potent, selective, orally active GnRH receptor antagonist that may have potential application as a therapeutic agent for treating hormone-dependent cancers and diseases.
引用
收藏
页码:688 / 695
页数:8
相关论文
共 50 条
  • [41] A novel conformation in a highly potent, constrained gonadotropin-releasing hormone antagonist
    Rizo, J
    Sutton, RB
    Breslau, J
    Koerber, SC
    Porter, J
    Hagler, AT
    Rivier, JE
    Gierasch, LM
    JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1996, 118 (05) : 970 - 976
  • [42] Regulation of Gonadotropin-Releasing Hormone (GnRH) Receptor-I Expression in the Pituitary and Ovary by a GnRH Agonist and Antagonist
    Mo, YaQin
    Peng, Ping
    Zhou, Ran
    He, ZuanYu
    Huang, LiLi
    Yang, DongZi
    REPRODUCTIVE SCIENCES, 2010, 17 (01) : 68 - 77
  • [43] Regulation of Gonadotropin-Releasing Hormone (GnRH) Receptor-I Expression in the Pituitary and Ovary by a GnRH Agonist and Antagonist
    YaQin Mo
    Ping Peng
    Ran Zhou
    ZuanYu He
    LiLi Huang
    DongZi Yang
    Reproductive Sciences, 2010, 17 : 68 - 77
  • [44] The discovery of novel small molecule non-peptide gonadotropin releasing hormone (GnRH) receptor antagonists
    Luthin, DR
    Hong, YF
    Pathak, VP
    Paderes, G
    Nared-Hood, KD
    Castro, MA
    Vazir, H
    Li, HT
    Tompkins, E
    Christie, L
    May, JM
    Anderson, MB
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2002, 12 (23) : 3467 - 3470
  • [45] DRUG-DRUG INTERACTION OF BUPROPION WITH ELAGOLIX, A NOVEL ORAL GONADOTROPIN-RELEASING HORMONE (GNRH) RECEPTOR ANTAGONIST.
    Polepally, A.
    Dharia, S.
    Shebley, M.
    Mostafa, N.
    Ali, F.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2020, 107 : S66 - S66
  • [46] PHARMACOKINETICS OF ELAGOLIX, A NOVEL ORAL GONADOTROPIN-RELEASING HORMONE (GnRH) ANTAGONIST, ADMINISTERED TO FEMALE SUBJECTS WITH RENAL IMPAIRMENT.
    Ng, J.
    Klein, C. E.
    Duan, W. R.
    Yan, J.
    Kaefer, A.
    Williams, L. A.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2015, 97 : S93 - S94
  • [47] Origins of gonadotropin-releasing hormone (GnRH) in vertebrates: Identification of a novel GnRH in a basal vertebrate, the sea lamprey
    Kavanaugh, Scott I.
    Nozaki, Masumi
    Sower, Stacia A.
    ENDOCRINOLOGY, 2008, 149 (08) : 3860 - 3869
  • [48] Steroid and pulsatile gonadotropin-releasing hormone (GnRH) regulation of luteinizing hormone and GnRH receptor in a novel gonadotrope cell line
    Turgeon, JL
    Kimura, Y
    Waring, DW
    Mellon, PL
    MOLECULAR ENDOCRINOLOGY, 1996, 10 (04) : 439 - 450
  • [49] A comparison of gonadotropin-releasing hormone (GnRH) antagonist and GnRH agonist flare protocols for poor responders undergoing in vitro fertilization
    Berin, Inna
    Stein, Daniel E.
    Keltz, Martin D.
    FERTILITY AND STERILITY, 2010, 93 (02) : 360 - 363
  • [50] In vitro fertilization cycle outcome after coasting in gonadotropin-releasing hormone (GnRH) agonist versus GnRH antagonist protocols
    Farhi, Jacob
    Ben-Haroush, Avi
    Lande, Yehezkel
    Sapir, Onit
    Pinkas, Haim
    Fisch, Benjamin
    FERTILITY AND STERILITY, 2009, 91 (02) : 377 - 382